Wisconsin 2023-2024 Regular Session

Wisconsin Assembly Bill AB753

Introduced
12/6/23  
Refer
12/6/23  

Caption

Creating a medicinal psilocybin treatment fund and a pilot program to study the effects of medicinal psilocybin treatment on patients with post-traumatic stress syndrome at the University of Wisconsin-Madison and making an appropriation. (FE)

Impact

The introduction of AB753 can significantly alter the state’s approach to mental health treatment for veterans. By promoting research into psilocybin therapy, this bill could pave the way for legal medicinal use of psychedelics in Wisconsin. Furthermore, as the University of Wisconsin-Madison collaborates with its Transdisciplinary Center for Research in Psychoactive Substances, the study results could potentially influence legislation regarding mental health treatments statewide and contribute to discussions around veteran care and innovative therapies.

Summary

Assembly Bill 753 establishes a pilot program to examine the effects of medicinal psilocybin treatment on veterans suffering from treatment-resistant post-traumatic stress syndrome (PTSD). The pilot program will be managed by the University of Wisconsin-Madison and is positioned to create a trust fund dedicated to providing resources for this initiative. Eligible participants must be veterans aged 21 and older, while law enforcement officers are excluded from participation. The therapy provided will follow regulatory pathways approved by the FDA, ensuring compliance with federal requirements.

Contention

Notable points of contention surrounding AB753 focus on the regulatory and societal implications of introducing psilocybin therapy. Critics may express concerns about safety, ethical considerations, and the long-term societal effects of legalizing psilocybin treatments. Additionally, there may be debates regarding funding allocations from general state revenues and the management of the newly created medicinal psilocybin treatment fund, emphasizing the need for transparency and accountability in the fund's expenditures.

Companion Bills

No companion bills found.

Previously Filed As

WI AB853

Funding for certain research positions at the University of Wisconsin-Madison and making an appropriation. (FE)

WI SB855

Funding for certain research positions at the University of Wisconsin-Madison and making an appropriation. (FE)

WI HM58

Study Psilocybin-based Medication Treatment

WI HB5588

Establish a regulated framework for the medical use of psilocybin to treat post-traumatic stress disorder (PTSD)

WI H4986

Relative to therapeutic psilocybin treatment centers

WI HB1717

Modifies provisions relating to alternative therapies and treatments, including psilocybin

WI HB829

Modifies provisions relating to alternative therapies and treatments, including psilocybin

WI HF620

A bill for an act relating to the production of psilocybin and the administration of psilocybin to persons with post-traumatic stress disorder, and providing penalties.(See HF 978.)

WI SB90

Modifies provisions relating to alternative therapies and treatments, including psilocybin

WI SB1767

Modifies provisions relating to alternative therapies and treatments, including psilocybin

Similar Bills

WA SB5921

Concerning psilocybin.

MA H2532

Relative to therapeutic psilocybin treatment centers

MA H4986

Relative to therapeutic psilocybin treatment centers

NH HB1796

allowing the use of psilocybin in approved clinical settings to treat qualified medical conditions.

NM SB219

Medical Psilocybin Act

NM HM58

Study Psilocybin-based Medication Treatment

HI SB1042

Relating To Mental Health.

WV HB5588

Establish a regulated framework for the medical use of psilocybin to treat post-traumatic stress disorder (PTSD)